S
Sirna Therapeutics
Biotech company using RNA interference-based therapies to change how diseases are treated
About Sirna Therapeutics
Sirna Therapeutics was a biotechnology company that specialized in the research and development of therapies based on RNA interference (RNAi). The company's primary focus was on small interfering RNA (siRNA), which are molecules capable of silencing specific genes associated with diseases. Sirna's business model revolved around leveraging its proprietary RNAi technology to create a pipeline of drug candidates for various human diseases. A notable milestone for the company was initiating the first-ever clinical trial for an siRNA-based drug, which targeted age-related macular degeneration (AMD), a common eye condition.
The company's market was the pharmaceutical and biotechnology industry, with a focus on therapies for genetic and other diseases that could be addressed by gene silencing. Sirna Therapeutics was acquired by Merck & Co. in 2006 for approximately $1.1 billion. This acquisition provided Merck with a significant entry into the RNAi field. However, in 2014, Merck sold Sirna Therapeutics to Alnylam Pharmaceuticals for $175 million. This transaction included Sirna's intellectual property, pre-clinical drug candidates, and other assets related to RNAi technology, which Alnylam, a leader in the RNAi space, integrated into its own development programs.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2006
- Outcome tier
- Unicorn$1–10B valuation tier
News
Open roles
Sirna Therapeutics in the San Francisco ecosystem
The Sirna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
Granite Ventures
Techno Venture Management
Venrock
Notable Capital
Sprout Group- OPOxford Bioscience Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Patents
26 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sirna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sirna Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

